Genelux (GNLX) Competitors $4.84 +0.02 (+0.41%) Closing price 02/21/2025 03:59 PM EasternExtended Trading$4.80 -0.04 (-0.93%) As of 02/21/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends GNLX vs. BCAX, VERV, MNMD, DNTH, AVXL, OPT, SANA, LENZ, QURE, and RLAYShould you be buying Genelux stock or one of its competitors? The main competitors of Genelux include Bicara Therapeutics (BCAX), Verve Therapeutics (VERV), Mind Medicine (MindMed) (MNMD), Dianthus Therapeutics (DNTH), Anavex Life Sciences (AVXL), Opthea (OPT), Sana Biotechnology (SANA), LENZ Therapeutics (LENZ), uniQure (QURE), and Relay Therapeutics (RLAY). These companies are all part of the "pharmaceutical products" industry. Genelux vs. Bicara Therapeutics Verve Therapeutics Mind Medicine (MindMed) Dianthus Therapeutics Anavex Life Sciences Opthea Sana Biotechnology LENZ Therapeutics uniQure Relay Therapeutics Bicara Therapeutics (NASDAQ:BCAX) and Genelux (NASDAQ:GNLX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, media sentiment, community ranking, risk, analyst recommendations, earnings and institutional ownership. Do analysts rate BCAX or GNLX? Bicara Therapeutics currently has a consensus target price of $41.20, suggesting a potential upside of 216.92%. Genelux has a consensus target price of $18.25, suggesting a potential upside of 277.07%. Given Genelux's stronger consensus rating and higher probable upside, analysts plainly believe Genelux is more favorable than Bicara Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bicara Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13Genelux 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 Do insiders & institutionals have more ownership in BCAX or GNLX? 37.3% of Genelux shares are owned by institutional investors. 9.3% of Genelux shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the MarketBeat Community believe in BCAX or GNLX? Genelux received 3 more outperform votes than Bicara Therapeutics when rated by MarketBeat users. CompanyUnderperformOutperformBicara TherapeuticsOutperform Votes11100.00% Underperform VotesNo VotesGeneluxOutperform Votes14100.00% Underperform VotesNo Votes Does the media prefer BCAX or GNLX? In the previous week, Bicara Therapeutics had 2 more articles in the media than Genelux. MarketBeat recorded 3 mentions for Bicara Therapeutics and 1 mentions for Genelux. Bicara Therapeutics' average media sentiment score of 0.58 beat Genelux's score of 0.00 indicating that Bicara Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bicara Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Genelux 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is BCAX or GNLX more profitable? Bicara Therapeutics' return on equity of 0.00% beat Genelux's return on equity.Company Net Margins Return on Equity Return on Assets Bicara TherapeuticsN/A N/A N/A Genelux N/A -105.05%-80.16% Which has higher earnings and valuation, BCAX or GNLX? Bicara Therapeutics has higher earnings, but lower revenue than Genelux. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBicara TherapeuticsN/AN/AN/AN/AN/AGenelux$170K983.37-$28.30M-$0.95-5.09 SummaryGenelux beats Bicara Therapeutics on 6 of the 11 factors compared between the two stocks. Get Genelux News Delivered to You Automatically Sign up to receive the latest news and ratings for GNLX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GNLX vs. The Competition Export to ExcelMetricGeneluxPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$167.17M$7.04B$5.77B$8.98BDividend YieldN/A2.87%4.78%3.85%P/E Ratio-5.096.1326.4618.82Price / Sales983.37309.83453.2580.30Price / CashN/A67.8344.0437.47Price / Book6.636.747.634.64Net Income-$28.30M$138.11M$3.18B$245.69M7 Day Performance-9.36%-2.43%-1.91%-2.66%1 Month Performance53.65%-1.91%-0.19%-2.15%1 Year Performance-29.65%-5.03%16.70%12.90% Genelux Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GNLXGenelux1.1791 of 5 stars$4.84+0.4%$18.25+277.1%-34.7%$166.13M$8,000.00-5.0910BCAXBicara TherapeuticsN/A$13.48+2.7%$41.20+205.6%N/A$733.58MN/A0.0032VERVVerve Therapeutics2.9199 of 5 stars$8.58+11.3%$25.75+200.1%-44.6%$726.42M$24.40M-3.49110Upcoming EarningsAnalyst ForecastMNMDMind Medicine (MindMed)2.3077 of 5 stars$9.89+14.3%$26.33+166.3%+65.2%$725.25MN/A-4.3840Gap UpHigh Trading VolumeDNTHDianthus Therapeutics1.7612 of 5 stars$24.49+1.5%$46.83+91.2%-1.3%$724.90M$2.83M-9.8080AVXLAnavex Life Sciences3.7939 of 5 stars$8.52+0.6%$44.00+416.4%+64.4%$722.67MN/A-16.3840Analyst ForecastAnalyst RevisionOPTOpthea2.0609 of 5 stars$5.21+1.0%$12.00+130.3%+46.8%$710.80M$120,000.000.008Upcoming EarningsGap UpSANASana Biotechnology3.0617 of 5 stars$3.16+12.5%$14.25+350.9%-62.3%$705.53MN/A-2.26380LENZLENZ Therapeutics1.4688 of 5 stars$25.22-0.2%$35.40+40.4%N/A$693.58MN/A0.00110QUREuniQure3.3789 of 5 stars$14.18+7.0%$40.00+182.1%+105.1%$691.13M$15.84M-2.86500Upcoming EarningsRLAYRelay Therapeutics1.6323 of 5 stars$4.00+1.0%$20.50+412.5%-62.6%$669.52M$25.55M-1.53330Positive News Related Companies and Tools Related Companies Bicara Therapeutics Alternatives Verve Therapeutics Alternatives Mind Medicine (MindMed) Alternatives Dianthus Therapeutics Alternatives Anavex Life Sciences Alternatives Opthea Alternatives Sana Biotechnology Alternatives LENZ Therapeutics Alternatives uniQure Alternatives Relay Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GNLX) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredThe Real Hillbilly ElegyThe mountains of Appalachia are incredible to behold. Spanning thousands of miles across Alabama, Kentucky...Porter & Company | SponsoredMajor AI announcement for 2025BIG NEWS: “Market Wizard” Larry Benedict Releases a Whole New Way to Trade AI StocksBrownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genelux Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Genelux With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
